Literature DB >> 19520944

Drug discovery. Repurposing with a difference.

Mark S Boguski1, Kenneth D Mandl, Vikas P Sukhatme.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19520944     DOI： 10.1126/science.1169920

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  65 in total

1.  Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm.

Authors:  Paul Wicks; Timothy E Vaughan; Michael P Massagli; James Heywood
Journal:  Nat Biotechnol       Date:  2011-04-24       Impact factor: 54.908

2.  Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer-Aided Drug Repurposing.

Authors:  Tudor I Oprea; Sonny Kim Nielsen; Oleg Ursu; Jeremy J Yang; Olivier Taboureau; Stephen L Mathias; Lrene Kouskoumvekaki; Larry A Sklar; Cristian G Bologa
Journal:  Mol Inform       Date:  2011-03-14       Impact factor: 3.353

3.  Virtual target screening: validation using kinase inhibitors.

Authors:  Daniel N Santiago; Yuri Pevzner; Ashley A Durand; MinhPhuong Tran; Rachel R Scheerer; Kenyon Daniel; Shen-Shu Sung; H Lee Woodcock; Wayne C Guida; Wesley H Brooks
Journal:  J Chem Inf Model       Date:  2012-07-23       Impact factor: 4.956

4.  Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment.

Authors:  Yasuteru Sakurai; Andrey A Kolokoltsov; Cheng-Chang Chen; Michael W Tidwell; William E Bauta; Norbert Klugbauer; Christian Grimm; Christian Wahl-Schott; Martin Biel; Robert A Davey
Journal:  Science       Date:  2015-02-27       Impact factor: 47.728

Review 5.  Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis.

Authors:  Judith M Graber; Shou-En Lu; Yong Lin; Grace Lu-Yao; Xiang-Lin Tan
Journal:  Curr Med Chem       Date:  2018       Impact factor: 4.530

6.  The STAT3 inhibitor pimozide impedes cell proliferation and induces ROS generation in human osteosarcoma by suppressing catalase expression.

Authors:  Nan Cai; Wei Zhou; Lan-Lan Ye; Jun Chen; Qiu-Ni Liang; Gang Chang; Jia-Jie Chen
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

7.  LINCS gene expression signature analysis revealed bosutinib as a radiosensitizer of breast cancer cells by targeting eIF4G1.

Authors:  Sai Hu; Dafei Xie; Pingkun Zhou; Xiaodan Liu; Xiaoyao Yin; Bo Huang; Hua Guan
Journal:  Int J Mol Med       Date:  2021-03-11       Impact factor: 4.101

8.  Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.

Authors:  Christopher C Gibson; Weiquan Zhu; Chadwick T Davis; Jay A Bowman-Kirigin; Aubrey C Chan; Jing Ling; Ashley E Walker; Luca Goitre; Simona Delle Monache; Saverio Francesco Retta; Yan-Ting E Shiu; Allie H Grossmann; Kirk R Thomas; Anthony J Donato; Lisa A Lesniewski; Kevin J Whitehead; Dean Y Li
Journal:  Circulation       Date:  2014-12-08       Impact factor: 29.690

9.  A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors.

Authors:  Sharangdhar S Phatak; Shuxing Zhang
Journal:  Pac Symp Biocomput       Date:  2013

Review 10.  Pharmacotherapy of amphetamine-type stimulant dependence: an update.

Authors:  Matthew Brensilver; Keith G Heinzerling; Steven Shoptaw
Journal:  Drug Alcohol Rev       Date:  2013-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.